000423.SZDong-E-E-Jiao Co.,Ltd.
This year, Dong-E-E-Jiao Co., Ltd. has to prove it can navigate the regulatory and pricing turbulence in the Traditional Chinese Medicine (TCM) space, with the Q3 2026 earnings and Singles' Day prep on October 28 serving as the first major test, anchoring the stock at $52.00 and setting the stage for a potential bull move to $56.00 or a bear retreat to $48.00. The next catalyst, the December 15 regulatory update, will either confirm the base case of a pullback or provide a rare upside catalyst, while the FY2026 earnings release in March 2027 will be the final test of whether the company can deliver on its dividend commitments and stabilize its profit profile.
The schedule
- Tue15Dec
Year-end regulatory adjustments for Traditional Chinese Medicine (TCM) pricing and potential reimbursement framework shifts.
- Fri26Feb
Q3 2026 earnings release and visibility into Q4 inventory build for the major November retail holidays.
- Fri26Mar
FY2026 annual earnings release and dividend declaration.
- Fri28May
- Fri27Aug
Past
- Fri28Aug
Actual outcome: Bear · $45.84 at outcome
Price reached or fell below bear floor ($44.50) at outcome date.
Q2 2026 interim earnings report, assessing if the recent 5.57% top-line and 7.02% net income growth can be sustained.